$3SBIO(01530)$ 我买入三生制药（01530），

6
1
Favorite

盲炳
02-05 09:36

$3SBIO(01530)$ 我买入三生制药（01530），核心看中其业绩稳健增长+创新管线高兑现的双重价值。公司2024年归母净利润同比增34.9%，特比澳、蔓迪等核心产品在细分领域市占率领先，医保续约+适应症拓展持续打开增长空间。创新端看点十足，PD-1/VEGF双抗SSGJ-707临床数据优异，与辉瑞合作2026年启动全球3期临床，自免领域多款管线进入后期阶段，商业化落地在即。同时公司对外合作频繁，全球化布局+产品矩阵完善，当前估值处于合理区间，业绩与管线双重驱动下，长期成长潜力显著。

01530

02-05 09:31

HK3SBIO

Side	Price \| Filled	Realized P&L
Buy Open	22.74 1,000	+1.68% Holding

3SBIO

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Top
Latest

LilithMonroe
·02-05 15:27
买得值！业绩稳增创新牛，长持赚翻了
Reply
Like
Report

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":529302800036592,"tweetId":"529302800036592","gmtCreate":1770255383877,"gmtModify":1770278419085,"author":{"id":4160043317841132,"idStr":"4160043317841132","authorId":4160043317841132,"authorIdStr":"4160043317841132","name":"盲炳","avatar":"https://community-static.tradeup.com/news/b36a6c05b78a7183f709007b5caf47ac","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":13,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.15","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.05","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":654,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":482,"starInvestorOrderShareNum":1411,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":90.75,"showRor":true,"investmentPhilosophy":"日日難過日日過，天天難贏天天驘!","winRationPercentage":87.429035,"tradeVolumeEst":0},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/01530\">$3SBIO(01530)$&nbsp;</a><span>我买入三生制药（01530），核心看中其业绩稳健增长+创新管线高兑现的双重价值。公司2024年归母净利润同比增34.9%，特比澳、蔓迪等核心产品在细分领域市占率领先，医保续约+适应症拓展持续打开增长空间。创新端看点十足，PD-1/VEGF双抗SSGJ-707临床数据优异，与辉瑞合作2026年启动全球3期临床，自免领域多款管线进入后期阶段，商业化落地在即。同时公司对外合作频繁，全球化布局+产品矩阵完善，当前估值处于合理区间，业绩与管线双重驱动下，长期成长潜力显著。</span></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/01530\">$3SBIO(01530)$&nbsp;</a><span>我买入三生制药（01530），核心看中其业绩稳健增长+创新管线高兑现的双重价值。公司2024年归母净利润同比增34.9%，特比澳、蔓迪等核心产品在细分领域市占率领先，医保续约+适应症拓展持续打开增长空间。创新端看点十足，PD-1/VEGF双抗SSGJ-707临床数据优异，与辉瑞合作2026年启动全球3期临床，自免领域多款管线进入后期阶段，商业化落地在即。同时公司对外合作频繁，全球化布局+产品矩阵完善，当前估值处于合理区间，业绩与管线双重驱动下，长期成长潜力显著。</span></body></html>","text":"$3SBIO(01530)$ 我买入三生制药（01530），核心看中其业绩稳健增长+创新管线高兑现的双重价值。公司2024年归母净利润同比增34.9%，特比澳、蔓迪等核心产品在细分领域市占率领先，医保续约+适应症拓展持续打开增长空间。创新端看点十足，PD-1/VEGF双抗SSGJ-707临床数据优异，与辉瑞合作2026年启动全球3期临床，自免领域多款管线进入后期阶段，商业化落地在即。同时公司对外合作频繁，全球化布局+产品矩阵完善，当前估值处于合理区间，业绩与管线双重驱动下，长期成长潜力显著。","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":3,"favoriteSize":0,"link":"https://ttm.financial/post/529302800036592","repostId":0,"isVote":1,"tweetType":1,"viewCount":221,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["01530"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"4160043317841132","orderId":"42120657837511680","kind":"TRADE","symbol":"01530","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/01530\">$3SBIO(01530)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/01530","symbolName":"3SBIO","market":"HK","action":"BUY","currency":"HKD","symbolLogo":"","showFilledQuantity":true,"nameCN":"3SBIO","orderType":"AL","filledQuantityFinal":1000,"avgFillPrice":22.74,"createTime":1770255110,"filledQuantity":"1000","filledQuantityScale":"0","openFlag":true,"side":"DEBIT","contractMajorDescription":"3SBIO","contractExtraDescription":"01530","legs":[],"completedFlag":false,"orderPnl":{"openRealizedPnlPercent":0,"openUnrealizedPnlPercent":0.0168},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":409,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":529427277907480,"commentId":"529427277907480","gmtCreate":1770276425502,"gmtModify":1770281950320,"authorId":9000000000000505,"author":{"id":9000000000000505,"idStr":"9000000000000505","authorId":9000000000000505,"name":"LilithMonroe","avatar":"https://static.tigerbbs.com/ffa846851f0117a4a0290ab42ff51115","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":529302800036592,"objectIdStr":"529302800036592","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"买得值！业绩稳增创新牛，长持赚翻了","text":"买得值！业绩稳增创新牛，长持赚翻了","html":"买得值！业绩稳增创新牛，长持赚翻了","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}